Antibody · IL-13

1개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1 programs
AntibodyCurated CoreFDAEli LillyApproved

lebrikizumab-lbkz (Ebglyss, LY3650150, lebrikizumab)

Moderate-to-severe atopic dermatitis · IL-13

#IL-13#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 108Status Approved